Bolus and Continuous Infusion Mitoxantrone in Newly Diagnosed Adult Acute Lymphoblastic Leukemia: Results of Two Consecutive Phase II Clinical Studies: Original Articles

References

• Copelan E A, McGuire E A. The biology and treatment of acute lymphoblastic leukemia in adults. Blood 1995; 85: 1151–1168
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Gale R P. Acute lymphoblastic leukemia in adults: Recent progress, future directions. Semin Hematol 1987; 24: 27–39
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Walters R L, Keating M J, et al. Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia. Cancer 1990; 65: 5–8
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Walters R S, Keating M J, et al. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard and high-risk acute lymphoblastic leukemia. J Clin Oncol 1990; 8: 994–1004
   PubMed Web of Science ®Google Scholar
• Arlin Z A, Feldman E J, Finger L R, et al. Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemia. Leukemia 1991; 5: 712–714
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Thiel E, Ludwig W D, et al. Follow-up of the first two successive German multicenter trials for adult ALL (01/81 and 02/84). German Adult ALL Study Group. Leukemia 1993; 7(Suppl 2)S130–134
   PubMed Web of Science ®Google Scholar
• Murdock K C, Child R G, Fabio P F, et al. Antitumor agents. 1. 1,4-Bis [(aminoalkyl)amino] 9,10-anthracenediones. J Med Chem 1979; 22: 1024–1030
   PubMed Web of Science ®Google Scholar
• Paciucci P A, Cuttner J, Holland J F, et al. Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia. Semin Oncol 1984; 11(Suppl l)36–40
   PubMedGoogle Scholar
• Hiddemann W, Buchner T H, Heil G, et al. Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM). Leukemia 1990; 4: 637–640
   PubMed Web of Science ®Google Scholar
• Benjamin R S. Rationale for the use of mitoxantrone in the older patient: cardiac toxicity. Semin Oncol 1995; 22(Suppl 1)11–13
   PubMed Web of Science ®Google Scholar
• Michelutti A, Damiani D, Michieli A, et al. Comparative toxicity of mitoxantrone, idarubicin and doxorubicin in sensitive and multidrug resistant human tumor cell lines. Haematologica 1991; 76(Suppl 4)76
   Google Scholar
• Greidanus J, de Vries E G, Mulder N H, et al. A phase I pharmacokinetic study of 21-day continuous infusion mitoxantrone. J Clin Oncol 1989; 7: 790–797
   PubMed Web of Science ®Google Scholar
• Bennett J M, Catovsky D, Daniel M T, et al. The French-American-British (FAB) Cooperative Group. The morphologic classification of acute lymphoblastic leukemia: Concordance among observers and clinical correlation. Br J Haematol 1981; 47: 553–561
   PubMed Web of Science ®Google Scholar
• Link M P, Warnke R A, Finlay J, et al. A single monoclonal antibody identifies T-cell lineage of childhood lymphoid malignancies. Blood 1983; 62: 722–728
   PubMed Web of Science ®Google Scholar
• Sobol R E, Mick R, Royston I, et al. Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. N Engl J Med 1987; 316: 1111–1117
   PubMed Web of Science ®Google Scholar
• Miller A B, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47: 207–214
   PubMed Web of Science ®Google Scholar
• Zubrod C G, Schneiderman M, Frei E, et al. Appraisal of methods for the study of chemotherapy in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J ChronDis 1960; 11: 7–33
   Google Scholar
• Kaplan E L, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457
   Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163–170
   PubMedGoogle Scholar
• Paciucci P A, Ohnuma T, Cuttner J, et al. Mitoxantrone in patients with acute leukemia in relapse. Cancer Res 1983; 43: 3919–3922
   PubMed Web of Science ®Google Scholar
• Moore J O, Olsen G A. Mitoxantrone in the treatment of relapsed and refractory acute leukemia. Semin Oncol 1984; 11(Suppl 1)41–46
   PubMedGoogle Scholar
• Arlin Z A, Silver R, Cassileth P, et al. Phase I–II trial of mitoxantrone in acute leukemia. Cancer Treat Rep 1985; 69: 61–64
   PubMedGoogle Scholar
• Hiddemann W, Kreutzmann H, Straif K, et al. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia. Semin Oncol 1987; 14(Suppl l)73–77
   PubMedGoogle Scholar
• Paciucci P A, Keaveney C, Cuttner J, et al. Mitoxantrone, vincristine, and prednisone in adults with relapsed or primarily refractory acute lymphocytic leukemia and terminal deoxynu-cleotidyl transferase positive blastic phase chronic myelocytic leukemia. Cancer Res 1987; 47: 5234–5237
   PubMed Web of Science ®Google Scholar
• Bezwoda W R, Bernasconi C, Hutchinson R M, et al. Mitoxantrone for refractory and relapsed acute leukemia. Cancer 1990; 66: 418–422
   PubMed Web of Science ®Google Scholar
• Lejeune C, Tubiana N, Gastaut J A, et al. High dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients. Eur J Haematol 1990; 44: 240–243
   PubMed Web of Science ®Google Scholar
• Milpied N, Gisselbrecht C, Harousseau J L, et al. Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy. Cancer 1990; 66: 627–631
   PubMed Web of Science ®Google Scholar
• Annino L, Giona F, Vegna M L, et al. Mitoxantrone in adult acute lymphoblastic leukemia (ALL): results of a salvage regimen in primary refractory patients. Haematologica 1991; 76(Suppl 4)53
   PubMedGoogle Scholar
• Arlin Z A, Feldman E J, Finger L R, et al. Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemia. Leukemia 1991; 5: 712–714
   PubMed Web of Science ®Google Scholar
• Hiddemann W. High-dose cytosine-arabinoside and mitoxantrone (HAM) in the treatment of acute leukemias: results of salvage and first line treatment. Haematologica 1991; 76(Suppl 4)53, (abstract)
   PubMedGoogle Scholar
• Keating M J, Kantarjian H, O'Brien S, et al. The M.D. Anderson Cancer Center experience with mitoxantrone in acute leukemia. Haematologica 1991; 76(Suppl 4)52, (abstract)
   Google Scholar
• Morra E, Lazzarino M, Pagnucco G, et al. Mitoxantrone with intermediate or high dose Ara-C for refractory acute lymphoblastic leukemia and lymphoma. Haematologica 1991; 76(Suppl 4)53
   PubMedGoogle Scholar
• Sousa A, Fernandes J, Mesquita V, et al. High-dose Ara-C and mitoxantrone in relapsed and refractory acute leukemia. Haematologica 1991; 76(Suppl 4)125
   Google Scholar
• Liso V, Specchia G, Capalbo S, et al. Mitoxantrone and continuous infusion of cytosine arabinoside in refractory and relapsed acute lymphoblastic leukemia. Acta Haematol 1992; 87: 54–57
   PubMed Web of Science ®Google Scholar
• Feldman E J, Alberts D S, Arlin Z, et al. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol 1993; 11: 2002–2009
   PubMed Web of Science ®Google Scholar
• Schiller G, Lee M, Territo M, et al. Phase II study of etoposide, ifosfamide, and mitoxantrone for the treatment of resistant adult acute lymphoblastic leukemia. Am J Hematol 1993; 43: 195–199
   PubMed Web of Science ®Google Scholar
• Keskin A, Tombuloglu M, Atamer M A, et al. Mitoxantrone and standard dose cytosine arabinoside therapy in refractory or relapsed acute leukemia. Acta Haematol 1994; 92: 14–17
   PubMed Web of Science ®Google Scholar
• Cuttner J, Mick R, Budman D R, et al. Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: A CALGB Study. Leukemia 1991; 5: 425–431
   PubMed Web of Science ®Google Scholar
• Weiss M, Maslak P, Feldman E, et al. Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone. J Clin Oncol 1996; 14: 2480–2485
   PubMed Web of Science ®Google Scholar
• Benjamin R S. Rationale for the use of mitoxantrone in the older patient: cardiac toxicity. Semin Oncol 1995; 22(Suppl 1)11–13
   PubMed Web of Science ®Google Scholar
• Schauer P, Arlin Z A, Mertelsmann R, et al. Treatment of acute lymphoblastic leukemia in adults: Results of the L-10 and L-10M protocols. J Clin Oncol 1983; 1: 462–470
   PubMed Web of Science ®Google Scholar
• Hussein K K, Dahlberg S, Head D, et al. Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation and maintenance chemotherapy. Blood 1989; 73: 57–63
   PubMed Web of Science ®Google Scholar
• Linker C A, Levitt L J, O'Donnell M, et al. Treatment of acute lymphoblastic leukemia in adults with intensive cyclical chemotherapy. Blood 1989; 74(Suppl 1)288
   Google Scholar
• Larson R A, Dodge R K, Burns C P, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood 1995; 85: 2025–2037
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Ludwig W D, Thiel E, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996; 87: 495–508
   PubMed Web of Science ®Google Scholar
• Niemeyer C M, Hitchcock-Bryan S, Sallan S E. Comparative analysis of treatment programs for childhood acute lymphoblastic leukemia. Semin Oncol 1985; 12: 122–130
   PubMed Web of Science ®Google Scholar
• Ludescher C, Eisterer W, Hilbe W, et al. Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia. Leukemia 1995; 9: 350–356
   PubMed Web of Science ®Google Scholar
• Sparano J A, Wiemik P H, Leaf A, et al. Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: Evidence for a schedule-dependent effect favoring infusional administration of chemotherapy. I Clin Oncol 1993; 11: 1071–1079
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Walters R S, Keating M J, et al. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol 1990; 8: 994–1004
   PubMed Web of Science ®Google Scholar